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Another Look at Bovine
Growth Hormone
A Focus article, "Extra Ingredients:
Hormones in Food," in the August issue of
EHP (102:632-635), included a brief but
well-researched and generally accurate
account of the debate over recombinant
bovine growth hormone (rbGH). But, in
quoting Consumers Union's Jean
Halloran, your report unduly emphasized
one narrow technical issue and left an erro-
neous impression ofwhy the CU opposes
the use ofrbGH.
Halloran did indeed note that the hor-
mone insulinlike growth factor 1 (IGF-1),
which is found at elevated levels in milk
from cows treated with rbGH, has been
shown to promote the growth of tumor
cells in laboratory experiments. However,
she made that point in the context of
explaining some of the unanswered ques-
tions about possible long-term public
health impacts of rbGH use. Exposure to
IGF-1 is one ofseveral issues on which the
CU believes more and better scientific data
are needed. But by emphasizing this point,
your report implied that CU currently
believes the use of rbGH increases con-
sumers' cancer risk. That is not the case.
CU has spoken out against the use of
rbGH for several years, and we will contin-
ue to do so. Our posture is based on a
broad analysis of the benefits, costs, and
risks to consumers of the use of this hor-
mone, not primarily on the narrower and
largely theoretical possiblility of increased
cancer risk. Whatever its perceived benefits
to the drug companies who sell it and the
dairy farmers who choose to use it, rbGH
offers no clear benefits to consumers. The
drug's purpose is to boost milk production,
but the U.S. already suffers from a surplus
of milk. Economic analyses indicate that
the retail prices ofmilk and milk products
do not go down in response to an increased
oversupply. But the federal government is
committed to buy surplus milk, and the
cost to taxpayers ofthat dairy-industry sup-
port program could increase by hundreds
of millions ofdollars in the next few years
because ofrbGH use. In addition, CU, like
the FDA, believes that use of rbGH will
increase the risk of udder infections in
treated cows, which in turn is likely to
result in increased antibiotic use, and may
produce aslight dedine in the average qual-
ity ofmilkfrom rbGH-treated herds.
Given these likely impacts of rbGH
use, and the lack ofany tangible benefit to
consumers to offset concern about unre-
solved questions of long-term health
impacts, we are not surprised that surveys
show a large majority of the public would
prefer not to buy milk from rbGH-treated
cows. CU believes consumers have the
right to make that choice, and the fate of
rbGH should be decided by market forces.
For those reasons, wewill continue to press
for appropriate labeling of milk and dairy
products from rbGH-treated cows.
Rhoda H. Karpatkin
Edward Groth III
Consumers Union
Yonkers, NewYork
Controlling Malaria
Since I started receiving EHP, I have again
"reawakened" my insatiable appetite for
biological investigations. The Focus article,
"Global Climate Change: Beyond Sun-
burn," in the May 1994 issue (102:440-
443) was particularly interesting because
for a long time now, I have argued the case
of strategic seasonal control of malaria
rather than the current approach of treat-
ing or curing the disease with different
antimalarial drugs. The biggest problem
we have in this part of the world is that
chloroquine does not seem to be that effec-
tive any longer. Approaches based on sea-
sonal climatic changes may offer a higher
chance of success in controlling malaria
than the current approach.
J. S. Phiri
Pesticides and Toxics Division
Environmental Council ofZambia
Lusaka, Zambia
A Matter of Nomenclature
I am writing to request your assistance in
ensuring that all future articles relating to
"glycol ethers" published in EHP use spe-
cific terminology to refer to the specific
compounds(s) rather than a general catego-
ry description.
The terms "glycol ethers" and "ethyl-
ene glycol ethers" are commonly, and
incorrectly, used to report data which are
only applicable to specific members ofthe
general chemical category. The term "gly-
col ethers" refers to a very broad group of
chemicals, which despite their structural
similarities, have demonstrated distinctly
different toxicityprofiles.
Over the past decade, many publica-
tions focused on the lowest molecular
weight ethylene glycol ethers, ethylene gly-
col ethyl ether (EGEE) and ethylene glycol
methyl ether (EGME). Studies in the early
1980s showed these compounds caused
adverse reproductive and developmental
effects in laboratory animals. As a result,
manufacturers for many years have recom-
mended against their use in any consumer
products and have kept occupational expo-
sure very low.
Higher molecular weight ethylene gly-
col monoethers that have been tested have
not been associated with significant adverse
developmental and reproductive effects. In
fact, the results of research on these com-
pounds contrast with the data on EGEE
and EGME. This is true in particular for
the largest volume product in the class,
ethylene glycol butyl ether (EGBE). EGBE
has been shown not to be a primary devel-
opmental, nor a reproductive, toxicant.
It is inappropriate to refer to the toxici-
ty of"glycol ethers." Each ofthe individual
compounds has demonstrated its own toxi-
city profile, with EGBE and other higher
molecular weight glycol ethers being ofrel-
atively low toxicity. Authors should be
careful when discussing any of these com-
pounds to identify them specifically. This
is particularly true in titles and abstracts
since the use ofthe generic term can imply
that the effects reported apply to all mem-
bers of the chemical class. We seek your
assistance in educating authors in these dis-
tinctions and recommend they identify the
specific subjects of their research in the
titles oftheir papers.
I would be glad to offer any additional
information to your journal or individual
authors to assist in improving the termi-
nology used for these compounds. In-
quiries should be addressed to Chemical
Manufacturers Association, 2501 M Street,
NW, Washington, DC 20037; phone:
(202) 887-1293.
Kathryn A. Rosica
Chemical Manufacturers Association
Washington, DC
Source for MCS Facts
The Human Ecology Action League, Inc.
(HEAL) was founded in 1977 as an infor-
mation and education organization con-
cerned with the health effects of environ-
mental exposures. One such health effect is
the phenomenon now generally known as
multiple chemical sensitivity (MCS). MCS
has been an important focus of HEAL's
information and education activities since
its inception.
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